Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing.

St John EP, Simen BB, Turenchalk GS, Braverman MS, Abbate I, Aerssens J, Bouchez O, Gabriel C, Izopet J, Meixenberger K, Di Giallonardo F, Schlapbach R, Paredes R, Sakwa J, Schmitz-Agheguian GG, Thielen A, Victor M, Metzner KJ, Däumer MP; 454 HIV-1 Alpha Study Group.

PLoS One. 2016 Jan 12;11(1):e0146687. doi: 10.1371/journal.pone.0146687. eCollection 2016.

2.

Minimum information for reporting next generation sequence genotyping (MIRING): Guidelines for reporting HLA and KIR genotyping via next generation sequencing.

Mack SJ, Milius RP, Gifford BD, Sauter J, Hofmann J, Osoegawa K, Robinson J, Groeneweg M, Turenchalk GS, Adai A, Holcomb C, Rozemuller EH, Penning MT, Heuer ML, Wang C, Salit ML, Schmidt AH, Parham PR, Müller C, Hague T, Fischer G, Fernandez-Viňa M, Hollenbach JA, Norman PJ, Maiers M.

Hum Immunol. 2015 Dec;76(12):954-62. doi: 10.1016/j.humimm.2015.09.011. Epub 2015 Sep 25.

3.

High throughput HLA genotyping using 454 sequencing and the Fluidigm Access Array™ System for simplified amplicon library preparation.

Moonsamy PV, Williams T, Bonella P, Holcomb CL, Höglund BN, Hillman G, Goodridge D, Turenchalk GS, Blake LA, Daigle DA, Simen BB, Hamilton A, May AP, Erlich HA.

Tissue Antigens. 2013 Mar;81(3):141-9. doi: 10.1111/tan.12071.

PMID:
23398507
4.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
5.

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.

Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.

Nat Med. 2006 Jul;12(7):852-5. Epub 2006 Jun 25. Erratum in: Nat Med. 2006 Oct;12(10):1220.

PMID:
16799556
6.

Drosophila in cancer research. An expanding role.

Potter CJ, Turenchalk GS, Xu T.

Trends Genet. 2000 Jan;16(1):33-9. Review.

PMID:
10637629
7.

The role of lats in cell cycle regulation and tumorigenesis.

Turenchalk GS, St John MA, Tao W, Xu T.

Biochim Biophys Acta. 1999 Oct 29;1424(2-3):M9-M16. Review. No abstract available.

PMID:
10528150
8.

Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity.

Tao W, Zhang S, Turenchalk GS, Stewart RA, St John MA, Chen W, Xu T.

Nat Genet. 1999 Feb;21(2):177-81.

PMID:
9988268

Supplemental Content

Loading ...
Support Center